An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma

Status Completed

Clinical Trial Summary

The aim of this study was to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.

Clinical Trial Description

Although there has been a significant increase in survival in many other cancer types through the years, no significant increase has been achieved in laryngeal SCC survival rates in the last 50 years. Despite the advancements in surgical techniques, organ preservation protocols and multidisciplinary approach, significant amount of patients have been living with morbidity or dying due to recurrence and metastasis. This lack of significant improvement in mortality rates creates the need for reliable and accurate biomarkers in early diagnosis, treatment and follow-up. Considering that the prognosis of two patients at the same clinical stage and treated with the same treatment protocol may differ, it suggests that there may be some differences at the molecular level apart from clinical stages. This study was mainly prepared to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value. To reach these aims, 60 patients who were prospectively and consecutively recruited from those who admitted to Hacettepe University, Department of Otorhinolaryngology, Ankara, Turkey, and were diagnosed with LSCC between May 2018 and February 2020. 20 healthy and age-matched controls were chosen from the hospital staff and relatives of the patients. Serum samples were obtained from all participants at the time of diagnosis, centrifuged and stored at -80 C. ELISA method will be used to analyze the serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin. Data analysis will reveal if there are any association between biomarker candidate molecules and clinical parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05217147
Study type	Observational
Source	Hacettepe University
Contact
Status	Completed
Phase
Start date	May 1, 2018
Completion date	August 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06016699` - Immunological Function After Radiation With Either Proton or Photon Therapy
Completed	`NCT03292341` - Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients.	N/A
Completed	`NCT03653039` - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy	N/A
Completed	`NCT05746780` - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting	`NCT05793151` - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy	N/A
Completed	`NCT01700647` - Breath Testing in Early and Late Larynx Cancer	N/A
Completed	`NCT00600223` - Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches	N/A
Completed	`NCT00169247` - Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation	Phase 2
Recruiting	`NCT03759431` - Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer	Phase 2
Active, not recruiting	`NCT02586207` - Pembrolizumab in Combination With CRT for LA-SCCHN	Phase 1
Recruiting	`NCT04057209` - VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer	N/A
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT06086119` - Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Suspended	`NCT04368702` - CONFIRM: Magnetic Resonance Guided Radiation Therapy	N/A
Active, not recruiting	`NCT03082534` - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma	Phase 2
Completed	`NCT00158652` - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC	Phase 3
Terminated	`NCT03479463` - Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
Completed	`NCT03096808` - Adaptive Radiotherapy for Head and Neck Cancer	Phase 2
Completed	`NCT03028766` - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer	Phase 1
Completed	`NCT00359645` - Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.